Under threat from Novartis, Biogen hails new data from SMA drug SpinrazaUnder threat from a gene therapy from Novartis, Biogen is making the case for its drug Spinraza for Share XUnder threat from Novartis, Biogen hails new data from SMA drug Spinrazahttps://pharmaphorum.com/news/under-threat-from-novartis-biogen-hails-new-data-from-sma-drug-spinraza/
AbbVie makes case for Humira follow-on upadacitinib at EULARThe summer medical conference season is well and truly upon us and much of the focus this week Share XAbbVie makes case for Humira follow-on upadacitinib at EULARhttps://pharmaphorum.com/news/abbvie-makes-case-for-humira-follow-on-upadacitinib-at-eular/
NHS chief hails SMA drug deal – and was that a swipe at Vertex?Children in England with the rare muscle wasting disease spinal muscular atrophy (SMA) will get access to Biogen’s Share XNHS chief hails SMA drug deal – and was that a swipe at Vertex?https://pharmaphorum.com/news/nhs-chief-hails-sma-drug-deal-and-was-that-a-swipe-at-vertex/
Biogen’s R&D strategy fails to impress after Alzheimer’s trial flopThe dust has settled at Biogen following the company’s disastrous announcement that it was ending development of Alzheimer’s Share XBiogen’s R&D strategy fails to impress after Alzheimer’s trial flophttps://pharmaphorum.com/news/biogens-rd-strategy-fails-to-impress-after-alzheimers-trial-flop/
US drug cost body calls for SMA drug price cutsA US drug cost-effectiveness group has said that Biogen should cut the price of its already-approved spinal muscular Share XUS drug cost body calls for SMA drug price cutshttps://pharmaphorum.com/news/us-drug-cost-body-calls-for-sma-drug-price-cuts/
MS drug market heats up as FDA backs Novartis’ new pillThe FDA has approved Novartis’ Mayzent (siponimod) multiple sclerosis pill for relapsing forms of the disease, dealing a Share XMS drug market heats up as FDA backs Novartis’ new pillhttps://pharmaphorum.com/news/ms-drug-market-heats-up-as-fda-backs-novartis-new-pill/
Biogen, Eisai hit hard as Alzheimer’s drug is abandonedThe dwindling number of amyloid-targeting drugs in development for Alzheimer’s disease (AD) has been reduced by one more, Share XBiogen, Eisai hit hard as Alzheimer’s drug is abandonedhttps://pharmaphorum.com/news/biogen-eisai-hit-hard-as-alzheimers-drug-is-abandoned/
Biogen buys UK gene therapy firm Nightstar for $800mBiogen has agreed to buy UK-based gene therapy biotech Nightstar, which focuses on using modified viruses as therapies Share XBiogen buys UK gene therapy firm Nightstar for $800mhttps://pharmaphorum.com/news/biogen-buys-uk-gene-therapy-firm-nightstar-for-800m/
R&D roundup – Sage impresses at JP MorganOne of the biggest headline-grabbers at the 2019 JP Morgan Healthcare conference this week was Sage Therapeutics unveiling Share XR&D roundup – Sage impresses at JP Morganhttps://pharmaphorum.com/r-d/views-analysis-r-d/rd-roundup-sage-impresses-at-jp-morgan/
